$GENB
Generate Biomedicines, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
$17.13
▲+0.06%+$0.010
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateGenerate Biomedicines, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
Why is GENB up today? It is at $17.13 (+0.06%), and our scanner flagged it 188 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment GENB spikes, and full due diligence on GENB — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $GENB 188 times in the last 30 days. Create a free account to track $GENB, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on GENB from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for GENB today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalystClinical / FDA update, from an SEC filing. Read it →Latest filing4Insider trade (Form 4)Sep 3, 2026 · 16 days ago| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Arnold Frances Director | Sold (automatic/other) | -1K | sold 0.4% | 231K | $16K at $16.00 | Sep 1, 26 |
Nally Michael Officer | Bought (open market) | +20K 0.02% of company | added 3.6% | 573K | $240K at $12.00 | Mar 4, 26 |
Afeyan Noubar Director | Acquired (grant/award) | +32.97M 25.7% of company | n/a | 13.70M | n/a | Mar 2, 26 |
Afeyan Noubar Director | Bought (open market) | +4.69M 3.7% of company | added 8.1% | 62.67M | $75.0M at $16.00 | Mar 2, 26 |
Mendillo Jane L Director | Bought (open market) | +2K | n/a | 2K | $24K at $16.00 | Mar 2, 26 |
Bancel Stephane Director | Acquired (grant/award) | +724K 0.6% of company | n/a | 724K | n/a | Mar 2, 26 |
Nally Michael Officer | Acquired (grant/award) | +658K 0.5% of company | added 40% | 2.32M | n/a | Mar 2, 26 |
Afeyan Noubar Director | Acquired (grant/award) | +32.97M 25.7% of company | n/a | 13.70M | n/a | Mar 2, 26 |
Afeyan Noubar Director | Bought (open market) | +4.69M 3.7% of company | added 8.1% | 62.67M | $75.0M at $16.00 | Mar 2, 26 |
Silvers Jason Officer | Bought (open market) | +2K | n/a | 2K | $32K at $16.00 | Mar 2, 26 |
Grous Beth Officer | Bought (open market) | +300 | n/a | 300 | $5K at $16.00 | Mar 2, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Comparable names in pharmaceutical preparations, closest in size first.
Here is the latest on GENB from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for GENB today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
GENB last traded at $17.13, up 0.06% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Generate Biomedicines, Inc. Common Stock (GENB) is next expected to report earnings on Thursday, November 5, 2026, about 46 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The GENB Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged GENB 188 times in the last 30 days.
GENB (Generate Biomedicines, Inc. Common Stock) trades on XNAS, with a market cap of about $2.20B in the PHARMACEUTICAL PREPARATIONS sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge GENB for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$GENB discussion
Sign in to ask a question or join the discussion.